The endocrine FGFs axis: A systemic anti-fibrotic response that could prevent pulmonary fibrogenesis?
Open Access
- 23 May 2024
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 259, 108669
Abstract
No abstract availableKeywords
This publication has 163 references indexed in Scilit:
- The regulation of FGF23 under physiological and pathophysiological conditionsPflügers Archiv - European Journal of Physiology, 2022
- NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic SteatohepatitisHepatology, 2019
- Fibroblast growth factor‐21 protects against fibrosis in hypertensive heart diseaseThe Journal of Pathology, 2018
- Fibroblast Growth Factor 15–Dependent and Bile Acid–Independent Promotion of Liver Regeneration in MiceHepatology, 2018
- NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled TrialHepatology Communications, 2018
- The ileal FGF15/19 to hepatic FGFR4 axis regulates liver regeneration after partial hepatectomy in miceJournal of Physiology and Biochemistry, 2018
- Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in miceHepatology Communications, 2017
- The Fibroblast Growth Factor signaling pathwayWIREs Developmental Biology, 2015
- Interleukin-1-induced acute bone resorption facilitates the secretion of fibroblast growth factor 23 into the circulationJournal of Bone and Mineral Metabolism, 2014
- Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and diseaseCell and tissue research, 2010